Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Anti-snoring device (unnamed), the most common co-covered peer. We currently track 1 Biotech story that mention Woomelang, all published on August 12, 2026.
Last mentioned: Aug 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Anti-snoring device (unnamed), the most common co-covered peer. We currently track 1 Biotech story that mention Woomelang, all published on August 12, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 11 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Woomelang. Shared-story counts are live from our verified record — not editorial picks.
Device reaches manufacturing stage
The U-shaped, ear-worn device with interchangeable ear pieces is reported to have progressed to manufacturing as the story is published.
Development project begins
Phil Jobson begins work on the anti-snoring device in his Woomelang shed (approximate start, derived from the 15-year timeline reported in 2026).
A Woomelang inventor's auditory-biofeedback snoring device has reached manufacturing after 15 years, but with only anecdotal efficacy and no formal clinical data, its path to TGA clearance and device-market credibility remains unresolved.
Source: mailtimes.com.au · warrackherald.com.au
Woomelang is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
